Jason M. Silversteen, DO
Clinical Lead, Outpatient Neurology Specialists | ChristianaCare
Newark, DE, UNITED STATES
Jason M. Silversteen is a board-certified neurologist and holds current medical licensure in Delaware.
Biography
Dr. Silversteen is a neurology specialist at ChristianaCare, where he is also director of the Comprehensive Multiple Sclerosis Center and serves as the clinical lead for the outpatient neurology specialists practice.
He is a board-certified neurologist and holds current medical licensure in Delaware. Dr. Silversteen has conducted clinical trials, delivered presentations and lectures, and authored papers on multiple sclerosis and its treatment to both students and practicing neurologists. He has also shared his expertise in the form of patient education and community service programs.
Areas of Expertise (5)
Autoimmune Neurology
Neuromyelitis Optica Spectrum Disorder
Transverse Myelitis
Autoimmune Encepahlitis
MOG Antibody Disease
Education (2)
Lake Erie College of Osteopathic Medicine: DO 2005
Arcadia University: BS, Biology 2001
Multimedia
Publications:
Documents:
Videos:
Audio/Podcasts:
Links and Image Galleries (1)
Media Appearances (1)
8 Ways to Ease MS Pain
Everyday Health online
2015-10-19
This is a great place to start. “You want to be sure you’re getting proper sleep, eating a healthy diet, and getting some form of exercise," says Dr. Silversteen. "You also want to be well rested — fatigue exacerbates pain...”
Selected Papers and Publications (2)
No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice
Current Medical Research and OpinionRobert Zivadinov, Nasreen Khan, Jonathan R. Korn, Ellen Lathi, Jason Silversteen, Jonathan Calkwood, Scott Kolodny, Diego Silva, Jennie Medin & Bianca Weinstock-Guttman
2018-02-02
The impact of multiple sclerosis (MS) center type on outcomes has not been investigated. This study aimed to evaluate baseline characteristics and clinical and magnetic resonance imaging (MRI) outcomes in patients with MS receiving fingolimod over 16 months’ follow-up at private or academic centers in the USA.
Assessing ‘No Evidence of Disease Activity’ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice
CNS DrugsBianca Weinstock-Guttman, Jennie Medin, Nasreen Khan, Jonathan R. Korn, Ellen Lathi, Jason Silversteen, Jonathan Calkwood, Diego Silva, Robert Zivadinov, On behalf of the MS-MRIUS Study Group
2017-12-21
‘No evidence of disease activity’ (NEDA), a composite measure of clinical and magnetic resonance imaging outcomes, provides a comprehensive assessment of disease activity, but is not extensively reported in clinical practice. NEDA-3 is defined as patients with no new/enlarged T2 or gadolinium-enhancing lesions, no relapses, and no disability progression (according to Expanded Disability Status Scale scores). NEDA-4 comprises the components of NEDA-3 and a fourth criterion of ≤ 0.4% annualized brain volume loss.
External Service & Affiliations (2)
- American Academy of Neurology : Member
- American Osteopathic Association : Member
Selected Honors & Awards (3)
Beaver College Distinguished Scholar Award (professional)
Beaver College Distinguished Scholar Award
The Posey Award at Graduate Hospital (professional)
The Posey Award at Graduate Hospital
Robert Schwartzman Neurology Resident of the Year Award (professional)
Robert Schwartzman Neurology Resident of the Year Award
